| Literature DB >> 19785729 |
Emeka I Nweze1, Elizabeth E Eze.
Abstract
BACKGROUND: The ethanolic extract of the leaves of Ocimium gratisimum L. (Lamiaceae), used in traditional medicine for the treatment of several ailments such as urinary tract, wound, skin and gastrointestinal infections, was evaluated for its antibacterial properties against four clinical bacteria isolates namely: Escherichia coli, Proteus mirabilis, Staphylococcus aureus and Pseudomonas aeruginosa and the antifungal properties using a clinical isolate of Candida albicans. A typed bacterium of Escherichia coli ATCC 11775 and another typed fungal strain of Candida albicans (ATCC 90028) were also included. The study also intended to verify if the concomitant administration of conventional antibiotics with Ocimium gratisimum which is normally taken as food (spice) will negatively affect its activity.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19785729 PMCID: PMC2762446 DOI: 10.1186/1472-6882-9-37
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Results of the phytochemical analysis of Ocimium gratissimum leaf extract
| Tannins | + |
| Cyanogenic glycosides | + |
| Anthroquinones | - |
| Saponins | + |
| Terpenes | ++ |
| Flavonoids | - |
| Alkaloids | + |
| Reducing sugar | ++ |
| Fats and oil | +++ |
| Steroidal aglycone | + |
Key: - Not present; +, present at low concentration; ++, present at moderate concentration; +++, present at high concentration
The inhibition zone diameters shown by the test isolates against different concentrations of the plant extract
| 19 | 13.5 | - | - | - | |
| 11 | 9.8 | - | - | - | |
| 22 | 21 | 20 | 11 | - | |
| - | - | - | - | - | |
| - | - | - | - | - | |
| 13 | 10 | - | - | - | |
| 16 | 13 | - | - | - | |
| DMSO | - | - | - | - | - |
Key: -, No inhibition. The values are average figures of three replicates.
Summary of the interaction of the plant extract and the various antibiotics
| CP | 16 | 16 | 0 | indifference | |
| SX | 15 | 15 | 0 | indifference | |
| PN | - | - | - | - | |
| SE | 24 | 22 | -8.33 | antagonism | |
| CP | 29 | 35 | 20.69 | synergism | |
| SX | 23 | 12 | -47.83 | antagonism | |
| PN | - | - | - | - | |
| SE | 29 | - | - | - | |
| CP | 15 | 25 | 66.67 | synergism | |
| SX | 24 | 26 | 8.33 | additive | |
| PN | 12 | 20 | 66.67 | synergism | |
| SE | 29 | 19 | -34.48 | antagonism | |
| CP | 35 | 42 | 20 | synergism | |
| SX | 10 | 12 | 20 | synergism | |
| PN | 16 | 10 | -37.5 | antagonism | |
| SE | 22 | 11 | -50 | antagonism | |
| CP | 39 | 40 | 2.56 | additive | |
| SX | 10 | 12 | 20 | synergism | |
| PN | 8 | 10 | 25 | synergism | |
| SE | 14 | 11 | -21.42 | antagonism | |
| 26 | 23 | -11.54 | antagonism | ||
| 38 | 30 | -7.14 | antagonism | ||
| KE | 21 | 27 | 28.57 | synergism | |
| NY | 24 | 32 | 33.33 | synergism |
Key: -, No activity; CP, 10 mg of ciprofloxacin; SX, 30 mg of septrin; SE, 30 mg of streptomycin; PN, 30 mg of ampicillin; KE, ketoconazole; NY, nystatin.; %, percentage; IZD, inhibition zone diameter.